%A Yang Hongjuan, Xie Conghua. %T Advances of second-line therapy for small-cell lung cancer %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.04.013 %P 290-293 %V 44 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10205.shtml} %8 2017-04-08 %X Small cell lung cancer (SCLC) is a highly malignant tumor, which is very sensitive to firstline chemotherapy, but easy to recurrence and metastasis early. So it always has poor prognosis. Secondline therapy for SCLC develops slowly. Topotecan is the only drug approved by US Food and Drug Administration as a secondline chemoradiotherapy. Numerous studies on molecular targeted therapy and immunotherapy are being carried out, but most of them have no or little benefit. Rovalpituzumab tesirine (RovaT) targeted antibodydrug conjugate (ADC) which is published at the 2016 American Society of Clinical Oncology Annual Meeting shows a good antitumor activity, which seems to bring a new dawn of molecular targeted therapy.